Hikma agrees exclusive licensing with Orion for its new Easyhaler product in MENA


Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orion Corporation of Finland (Orion), for its new Easyhaler combination product

The Easyhaler is a dry powder inhaler (DPI) of budesonide and formoterol, for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Under the terms of the agreement, Hikma has the exclusive rights to register, distribute, market and sell the product in all of its MENA markets, leveraging Hikma’s strong local presence, sales and marketing capabilities and regulatory expertise.

Sign up for your free email newsletter

Markku Huhta-Koivisto, Senior Vice President of Orion's Proprietary Products division, said: "We’re confident that the good momentum we have for our Easyhaler products will continue and that this partnership with Hikma will strengthen Orion's strategic objective to become a stronger player in the field of respiratory medication.